Scholarlink

<p>Eosinophilic pneumonia secondary to drug exposure is a recognized but infrequent complication associated with a variety of medications, including oncological therapies. Among immunomodulatory drugs, pulmonary toxicity has been described for thalidomide and lenalidomide but remains a rare complication.</p><p>Pomalidomide is a third-generation immunomodulatory agent used in relapsed or refractory multiple myeloma. It has been authorized in Europe since 2013. To date, only a limited number of cases of pomalidomide-induced lung injury, and even fewer cases of eosinophilic pneumonia, have been documented in the literature.</p><p>We present a case of eosinophilic pneumonia attributed to pomalidomide in a 67-year-old patient receiving daratumumab, pomalidomide, and dexamethasone for relapsed multiple myeloma. The diagnosis was supported by compatible respiratory symptoms and imaging, bronchoalveolar lavage eosinophilia, exclusion of alternative causes, lack of clinical improvement with empirical antibiotics, and rapid improvement after pomalidomide withdrawal and systemic corticosteroid therapy.</p><p>Prompt recognition of this rare adverse event, discontinuation of pomalidomide, and corticosteroid therapy resulted in rapid clinical and radiological improvement, with sustained pulmonary function recovery at 12-month follow-up.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pomalidomide-induced acute eosinophilic pneumonia: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月20日

查看全文
  • Mathieu Megevet,
  • Jessica Freitas Pereira,
  • Jeanne Vervier,
  • Pierre-Yves Lovey,
  • Vincent Soubeyran,
  • Pierre-Olivier Bridevaux

摘要

Eosinophilic pneumonia secondary to drug exposure is a recognized but infrequent complication associated with a variety of medications, including oncological therapies. Among immunomodulatory drugs, pulmonary toxicity has been described for thalidomide and lenalidomide but remains a rare complication.

Pomalidomide is a third-generation immunomodulatory agent used in relapsed or refractory multiple myeloma. It has been authorized in Europe since 2013. To date, only a limited number of cases of pomalidomide-induced lung injury, and even fewer cases of eosinophilic pneumonia, have been documented in the literature.

We present a case of eosinophilic pneumonia attributed to pomalidomide in a 67-year-old patient receiving daratumumab, pomalidomide, and dexamethasone for relapsed multiple myeloma. The diagnosis was supported by compatible respiratory symptoms and imaging, bronchoalveolar lavage eosinophilia, exclusion of alternative causes, lack of clinical improvement with empirical antibiotics, and rapid improvement after pomalidomide withdrawal and systemic corticosteroid therapy.

Prompt recognition of this rare adverse event, discontinuation of pomalidomide, and corticosteroid therapy resulted in rapid clinical and radiological improvement, with sustained pulmonary function recovery at 12-month follow-up.